This article is about a pharmaceutical company that to not disclosing important safety information about drugs, and for promoting two popular drugs, Paxil and Welbutrin, for unapproved uses. The irony is that the FDA approves drugs that kill 100,000 people a year, and allows accelerated approval of drugs, which then allows the drugs to be sold to the public before they have completed clinical testing.
It’s even more ironic when the Deputy Attorney General James M. Cole said they “will not tolerate health care fraud,” considering Obamacare will now be forcing Americans to pay taxes to insurance companies, or one could say, incur penalties for not purchasing a government product. Either way you phrase it, it is wrong, with the bill being sold to Americans under the fraudulence of the fake liberal Obama and his endless list of broken promises and lies. Add to that the fact that Liz Fowler, VP of Wellpoint, one of the biggest insurance companies, had a large part in writing the health care reform bill. Politico.com said
“As a senior aide to Baucus, she directs the Finance Committee health care staff, enforces deadlines on drafting bill language and coordinates with the White House and other lawmakers. She also troubleshoots, identifying policy and political problems before they ripen. Max Baucus thanked her in writing.
“I wish to single out one person, and that one person is sitting next to me. Her name is Liz Fowler. Liz Fowler is my chief health counsel. Liz Fowler has put my health care team together. Liz Fowler worked for me many years ago, left for the private sector, and then came back when she realized she could be there at the creation of health care reform because she wanted that to be, in a certain sense, her profession lifetime goal. She put together the White Paper last November–2008–the 87-page document which became the basis, the foundation, the blueprint from which almost all health care measures in all bills on both sides of the aisle came.“
GlaxoSmithKline Settles Largest Health Care Fraud Case In U.S. History | Huffington Post
WASHINGTON (AP) — GlaxoSmithKline LLC will pay $3 billion and plead guilty to promoting two popular drugs for unapproved uses and to failing to disclose important safety information on a third in the largest health care fraud settlement in U.S. history, the Justice Department said Monday.
The $3 billion fine also will be the largest penalty ever paid by a drug company, Deputy Attorney General James M. Cole said. The corporation also agreed to be monitored by government officials for five years to attempt to ensure the company’s compliance, Cole said.
“Let me be clear, we will not tolerate health care fraud,” Cole told a news conference at the Justice Department. He would not say whether any company executives were under investigation. The company’s guilty plea and sentence have to be approved by a federal court in Massachusetts.
“For far too long, we have heard that the pharmaceutical industry views these settlements merely as the cost of doing business,” Acting Assistant Attorney General Stuart F. Delery, head of Justice’s civil division, said at the news conference. “That is why this administration is committed to using every available tool to defeat health care fraud.”
Delery added, “Today’s resolution seeks not only to punish wrongdoing and recover taxpayer dollars, but to ensure GSK‘s future compliance with the law.” He noted that a similar recent settlement with Abbott Laboratories also included continuing compliance monitoring.
It is illegal to promote uses for a drug that have not been approved by the Food and Drug Administration — a practice known as off-label marketing.
Prosecutors said GlaxoSmithKline illegally promoted the drug Paxil for treating depression in children from April 1998 to August 2003, even though the FDA never approved it for anyone under age 18. The corporation also promoted the drug Wellbutrin from January 1999 to December 2003 for weight loss, the treatment of sexual dysfunction, substance addictions and attention deficit hyperactivity disorder, although it was only approved for treatment of major depressive disorder.